Judge Bars Antitrust Claims in MedImmune's Patent Suit Vs. Genentech

Law360, New York (December 29, 2003, 12:00 AM EST) -- In a case with wide-ranging implications for licensing in the biotechnology sector, a U.S. District Court has ruled that MedImmune cannot pursue antitrust claims in its suit to invalidate a patent controlled by Genentech.

Medimmune had sued Genentech, Celltech, and others, in the U.S. District Court for the Central District of California in April this year, claiming that Genentech and Celltech entered into a collusive, anticompetitive agreement designed to extend the patent monopoly over what Genentech calls "the 'fundamental technology' required for the artificial synthesis of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.